Skip to main content

18-05-2021 | COVID-19 | News

News in brief

Inflammatory arthritis linked to lower COVID-19 hospitalization risk than other RMDs

Claire Barnard

medwireNews: Findings from the COVID-19 Global Rheumatology Alliance (C19-GRA) suggest that people with inflammatory arthritis may have a lower risk for hospitalization than those with other rheumatic and musculoskeletal diseases (RMDs).

Richard Conway (St James’s Hospital, Dublin, Ireland) and colleagues evaluated the outcomes of 105 people with RMDs and COVID-19 in Ireland who were included in the registry between March and August 2020. The most common diagnosis was inflammatory arthritis (41.9%), followed by connective tissue disease and others (23.8%, including systemic lupus erythematosus, polymyalgia rheumatic, and giant cell arteritis), and gout (20.0%).

A total of 25% of patients with inflammatory arthritis required hospital admission, as did 54% of those in the connective tissue disease group and 100% of those with gout. These findings translated into a significantly lower risk for hospitalization among patients with versus without inflammatory arthritis on multivariable analysis, with an adjusted odds ratio (aOR) of 0.09.

Although gout appeared to be a risk factor for hospitalization, this finding “may reflect selection bias and requires future evaluation,” say the researchers. They explain in Rheumatology Advances in Practice that “[g]out is usually managed in primary care in Ireland and since the C19-GRA is a rheumatologist-entered registry these cases could be less likely to be entered.”

In accordance with previous studies, the researchers also identified age (aOR=1.06), number of comorbidities (aOR=1.93), and glucocorticoid use (aOR=15.01) as significant predictors of hospitalization. Use of conventional or biologic DMARDs was not associated with hospitalization risk.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

18 May 2021: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.

Rheumatol Adv Pract 2021; doi:10.1093/rap/rkab031

COVID-19 vaccination in patients with rheumatic diseases

Get answers to key questions with recommendations from professional organizations

Anifrolumab for the treatment of lupus

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

JAK inhibitor safety

Data summary and expert discussion on the potential risks associated with JAK inhibitors.